Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Zhao, Yong ^a   Jiang, Zhaoshun ^b   Zhao, Tingbao ^b   Ye, Mingliang ^b   Hu, Chengjin ^b   Yin, Zhaohui ^b   Li, Heng ^c   Zhang, Ye ^d   Diao, Yalin ^b   Li, Yunxiang ^b   Chen, Yingjian ^b   Sun, Xiaoming ^b   Fisk, Mary B ^e   Skidgel, Randal ^a   Holterman, Mark ^a   Prabhakar, Bellur ^a   Mazzone, Theodore ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d Jinan Tianhe Stem Cell Biotechology Co Ltd   (China)

^e Texas Cord Blood Bank   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CD28 ANTIGEN; HEMOGLOBIN A1C; INDUCIBLE T CELL COSTIMULATOR LIGAND; INSULIN; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTIPOTENT STEM CELL; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TH1 TH2 BALANCE; TH3 CELL; BLOOD; CELL COMMUNICATION; CELL CULTURE; CLINICAL TRIAL; CONVALESCENCE; CYTOLOGY; FETUS BLOOD; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; REGENERATION; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ADOLESCENT; ADULT; C-PEPTIDE; CELL COMMUNICATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; FEMALE; FETAL BLOOD; FOLLOW-UP STUDIES; HUMANS; IMMUNOMODULATION; INSULIN-SECRETING CELLS; MALE; MULTIPOTENT STEM CELLS; RECOVERY OF FUNCTION; REGENERATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84855491166     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-3     Document Type: Article

References (42)

1. Couzin-Frankel J. Trying to reset the clock on type 1 diabetes. Science 2011, 333:819-821. 10.1126/science.333.6044.819, 21835995.
2. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300. 10.1038/nature08933, 20432533.
3. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, . Type 1 Diabetes TrialNet GAD Study Group Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327. 10.1016/S0140-6736(11)60895-7, 21714999, Type 1 Diabetes TrialNet GAD Study Group.
4. Bach JF. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011, 378:459-460. 10.1016/S0140-6736(11)60980-X, 21719098.
5. Mathieu C, Gillard P. Arresting type 1 diabetes after diagnosis: GAD is not enough. Lancet 2011, 378:291-292. 10.1016/S0140-6736(11)60978-1, 21715000.
6. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011, 91:79-118. 10.1152/physrev.00003.2010, 21248163.
7. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?. Nat Rev Endocrinol 2010, 6:149-157. 10.1038/nrendo.2009.275, 20173776.
8. Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does Type 1 diabetes develop?: the notion of homicide or {beta}-cell suicide revisited. Diabetes 2011, 60:1370-1379. 10.2337/db10-1797, 21525508.
9. Zhao Y, Mazzone T. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmun Rev 2010, 10:103-107. 10.1016/j.autrev.2010.08.011, 20728583.
10. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008, 57:1759-1767. 10.2337/db08-0180, 2453631, 18586907.
11. Aguayo-Mazzucato C, Bonner-Weir S. Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 2010, 6:139-148. 10.1038/nrendo.2009.274, 20173775.
12. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736. 10.1038/nri2395, 19172693.
13. Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett 2007, 108:78-87. 10.1016/j.imlet.2006.10.007, 17161871.
14. Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS ONE 2009, 4:e4226. 10.1371/journal.pone.0004226, 2627485, 19156219.
15. Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ. New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Transl Res 2010, 155:211-216. 10.1016/j.trsl.2010.01.003, 20403575.
16. Zhao Y, Wang H, Mazzone T. Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res 2006, 312:2454-2464. 10.1016/j.yexcr.2006.04.008, 16716296.
17. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608. 10.1056/NEJMoa043980, 15972866.
18. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920. 10.1056/NEJMoa0804328, 18843118.
19. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol 2008, 28:677-684. 10.1007/s10875-008-9242-z, 18716861.
20. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007, 7:585-598. 10.1038/nri2138, 17653126.
21. Leslie M. Immunology Regulatory T cells get their chance to shine. Science 2011, 332:1020-1021. 10.1126/science.332.6033.1020, 21617049.
22. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645. 10.1016/j.immuni.2009.04.010, 19464986.
23. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008, 134:392-404. 10.1016/j.cell.2008.07.025, 18692464.
24. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011, 241:180-205. 10.1111/j.1600-065X.2011.01011.x, 21488898.
25. Hombach AA, Kofler D, Hombach A, Rappl G, Abken H. Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol 2007, 179:7924-7931.
26. Hori S. c-Rel: a pioneer in directing regulatory T-cell lineage commitment?. Eur J Immunol 2010, 40:664-667. 10.1002/eji.201040372, 20162555.
27. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003, 171:3348-3352.
28. Vang KB, Yang J, Pagan AJ, Li LX, Wang J, Green JM, Beg AA, Farrar MA. Cutting edge: CD28 and c-Rel-dependent pathways initiate regulatory T cell development. J Immunol 2010, 184:4074-4077. 10.4049/jimmunol.0903933, 2851483, 20228198.
29. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004, 199:1479-1489. 10.1084/jem.20040179, 2211778, 15184501.
30. Gotsman I, Grabie N, Gupta R, DaCosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055. 10.1161/CIRCULATIONAHA.106.633263, 17060381.
31. Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol Rev 2011, 241:133-144. 10.1111/j.1600-065X.2011.01012.x, 21488895.
32. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011, 241:260-268. 10.1111/j.1600-065X.2011.01018.x, 21488902.
33. Metzger TC, Anderson MS. Control of central and peripheral tolerance by Aire. Immunol Rev 2011, 241:89-103. 10.1111/j.1600-065X.2011.01008.x, 21488892.
34. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009, 27:287-312. 10.1146/annurev.immunol.25.022106.141532, 19302042.
35. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009, 10:1185-1192. 10.1038/ni.1790, 2778301, 19783989.
36. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simões BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576. 10.1001/jama.297.14.1568, 17426276.
37. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698. 10.1056/NEJMoa012864, 12037148.
38. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, . Type 1 Diabetes TrialNet Abatacept Study Group Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419. 10.1016/S0140-6736(11)60886-6, 21719096, Type 1 Diabetes TrialNet Abatacept Study Group.
39. Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol 2011, 33:9-21. 10.1007/s00281-010-0205-0, 20424842.
40. Luo X, Yang H, Kim IS, Saint-Hilaire F, Thomas DA, De BP, Ozkaynak E, Muthukumar T, Hancock WW, Crystal RG, Suthanthiran M. Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 2005, 79:1091-1096. 10.1097/01.TP.0000161223.54452.A2, 15880049.
41. Chung CH, Hao E, Piran R, Keinan E, Levine F. Pancreatic beta-cell neogenesis by direct conversion from mature alpha-cells. Stem Cells 2010, 28:1630-1638. 10.1002/stem.482, 20653050.
42. Zhao Y, Huang Z, Lazzarini P, Wang Y, Di A, Chen M. A unique human blood-derived cell population displays high potential for producing insulin. Biochem Biophys Res Commun 2007, 360:205-211. 10.1016/j.bbrc.2007.06.035, 17588534.